Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms

Journal of Psychopharmacology

Volumn 24, Issue 6, 2010, Pages 861-866

  Poyurovsky, M ^a   Glick, I ^b   Koran, L M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depressive symptoms; Efficacy; Lamotrigine; Obsessive compulsive symptoms; Schizophrenia; Tolerability

Indexed keywords

ALPRAZOLAM; BIPERIDEN; CLOMIPRAMINE; DIAZEPAM; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; OLANZAPINE; QUETIAPINE; SERTRALINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CALGARY DEPRESSION RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALE; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; COMPULSIVE BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OBSESSIVE BEHAVIOR; PATIENT SELECTION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 77952981052     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108099215     Document Type: Article

References (35)

1. Addington, D., Addington, J., Schissel, B. (1990) A depression rating scale for schizophrenics. Schizophr Res 3: 247-251.
2. Anand, A., Charney, DS, Oren, DA, Berman, RM, Hu, XS, Cappiello, A., et al. (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57: 270-276.
3. Andreasen, NC (1983) Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
4. Andreasen, NC (1984) Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
5. Chakrabarty, K., Bhattacharyya, S., Christopher, R., Khanna, S. (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30: 1735-1740.
6. de Haan, L., Hoogenboom, B., Beuk, N., van Amelsvoort, T., Linszen, D. (2005) Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can J Psychiatry 50: 519-524.
7. de Haan, L., Hoogeboom, B., Beuk, N., Wouters, L., Dingemans, PM, Linszen, DH (2006) Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull 39: 25-30.
8. Fenton, WS, McGlashan, TH (1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143: 437-441.
9. Glick, I., Poyurovsky, M., Ivanova, O., Koran, LM (2008) Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. J Clin Psychiatry (in press).
10. Goff, DC, Keefe, R., Citrome, L., Davy, K., Krystal, JH, Large, C., et al. (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27: 582-589.
11. Goodman, WK, Price, LH, Rasmussen, SA, Mazure, C., Fleischmann, RL, Hill, CL, et al. (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011.
12. Green, AI, Canuso, CM, Brenner, MJ, Wojcik, JD (2003) Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26: 115-139.
13. Javitt, DC (2007) Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine-Glutamate Interactions. Int Rev Neurobiol 78: 69-108.
14. Ketter, TA, Brooks, JO, Hoblyn, JC, Champion, LM, Nam, JY, Culver, JL, et al. (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res 43: 13-23.
15. Ketter, TA, Calabrese, JR (2002) Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 63: 146-151.
16. Kremer, I., Vass, A., Gorelik, I., Bar, G., Blanaru, M., Javitt, DC, et al. (2004) Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 56: 441-446.
17. Krystal, JH, Perry Jr, EB, Gueorgieva, R., Belger, A., Madonick, SH, Abi-Dargham, A., et al. (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62: 985-994.
18. Kumar, TC, Khanna, S. (2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34: 527-528.
19. Nechmad, A., Ratzoni, G., Poyurovsky, M., Meged, S., Avidan, G., Fuchs, C., et al. (2003) Obsessive-compulsive disorder in adolescent schizophrenia patients. Am J Psychiatry 160: 1002-1004.
20. Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., et al. International Treatment Refractory OCD Consortium. (2002) Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5: 181-191.
21. Patil, ST, Zhang, L., Martenyi, F., Lowe, SL, Jackson, KA, Andreev, BV, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
22. Pittenger, C., Krystal, JH, Coric, V. (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3: 69-81. (Pubitemid 43276634)
23. Poyurovsky, M., Bergman, J., Weizman, R. (2006) Obsessive-compulsive disorder in elderly schizophrenia patients. J Psychiatr Res 40: 189-191.
24. Poyurovsky, M., Dorfman-Etrog, P., Hermesh, H., Munitz, H., Tollefson, GD, Weizman, A. (2000) Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol 15: 169-173.
25. Poyurovsky, M., Fuchs, C., Weizman, A. (1999) Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry 156: 1998-2000.
26. Poyurovsky, M., Kriss, V., Weisman, G., Faragian, S., Schneidman, M., Fuchs, C., et al. (2005 a) Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. Am J Med Genet B Neuropsychiatr Genet 133: 31-36.
27. Poyurovsky, M., Weizman, A., Weizman, R. (2004) Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 18: 989-1010. (Pubitemid 39612010)
28. Poyurovsky, M., Weizman, R., Weizman, A., Koran, L. (2005 b) Memantine for treatment-resistant OCD. Am J Psychiatry 162: 2191-2192.
29. Simpson, GM, Angus, JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl). 11-19.
30. Simpson, HB, Huppert, JD, Petkova, E., Foa, EB, Liebowitz, MR (2006) Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 67: 269-276.
31. Tibbo, P., Kroetsch, M., Chue, P., Warneke, L. (2000) Obsessive-compulsive disorder in schizophrenia. J Psychiatr Res 34: 139-146.
32. Tiihonen, J., Hallikainen, T., Ryynänen, OP, Repo-Tiihonen, E., Kotilainen, I., Eronen, M., et al. (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54: 1241-1248.
33. van Nimwegen, L., de Haan, L., van Beveren, N., Laan, W., van den Brink, W., Linszen, D. (2008) Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J Clin Psychopharmacol 28: 214-218.
34. Whiteside, SP, Port, JD, Deacon, BJ, Abramowitz, JS (2006) A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 146: 137-147.
35. Zoccali, R., Muscatello, MR, Bruno, A., Cambria, R., Mic, U., Spina, E., et al. (2007) The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 93: 109-116.